Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
ADK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ADK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ADK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AAK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AAK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of AAK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS7 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ACTMAP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ACTMAP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ACTMAP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ABL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ABL1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of ABL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TMPRSS12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TMPRSS12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of TMPRSS12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →